



ASX Release

2 October 2024

FY24 R&D Tax Incentive rebate received

Melbourne, Australia; Acrux Limited (ASX:ACR) is pleased to announce it has received its FY24 R&D Tax Incentive rebate ('RDTI') from the Australian Tax Office ('ATO') totalling \$2,728,021 and the associated short term funding facility provided by Radium Capital has been repaid in full.

Furthermore, the ATO has advised Acrux that its application for a new Overseas Finding for a recently commenced development project has been successful. This means that additional FY24 and future overseas expenditure on this project is eligible for the RDTI. Accordingly, an amendment will be submitted which will add to the FY24 RDTI already received.

The RDTI is an Australian Federal Government program under which companies may receive cash rebates for eligible research and development expenditure.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit www.acrux.com.au

For personal use only